睿知中国医院研究地图
候选清单

邀请入组淋巴瘤I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由浙江大学医学院附属第二医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06827782,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 9

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(9 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Diffuse large B-cell lymphoma (DLBCL) was confirmed by histology. CD19 expression was positive by lymphoma pathology or flow cytometry, and CD19 expression was ≥20% by IHC.

    入选标准第 4 条

  3. Patients who received antitumor therapy in the early stage but did not recover toxicity (CTCAE 5.0 toxicity did not recover to ≤ grade 1, except fatigue, anorexia, alopecia);

    排除标准第 9 条

  4. Meets any of the following definitions for refractory/relapsed CNS lymphoma: no complete response has been achieved with prior 2-line regimen including methotrexate or cytarabine-based regimen; Disease progression during any treatment; The stable time of disease after effective treatment is less than 6 months; Disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation.

    入选标准第 6 条

    Previous autologous hematopoietic stem cell transplantation is allowed, and the interval between stem cell transfusion and CAR-NK transfusion is ≥3 months;

    入选标准第 18 条

    Previous CAR-T cell therapy is allowed, and the time interval between CAR-T transfusion and CAR-NK transfusion is ≥3 months;

    入选标准第 19 条

    Have received gene therapy within the past 3 months;

    排除标准第 5 条

  5. ECOG score 0-3 points;

    入选标准第 9 条

  6. Creatinine clearance (Cockcroft-Gault method) ≥60 mL/min;

    入选标准第 12 条

    Serum total bilirubin and alkaline phosphatase ≤1.5× UNL;

    入选标准第 13 条

    Blood routine: absolute number of neutrophils >×109/L, platelet count 45×109/L, hemoglobin 80g/L;

    入选标准第 17 条

  7. Imaging showed the presence of at least one measurable lesion, with a minimum diameter of ≥10mm;

    入选标准第 7 条

  8. Persons infected with hepatitis B (HBsAg positive, but HBV-DNA<103 is not excluded) or hepatitis C virus (including virus carriers), syphilis and other acquired and congenital immunodeficiency diseases, including but not limited to HIV-infected persons;

    排除标准第 7 条

  9. Female subjects of childbearing age must test negative for pregnancy and agree to use effective contraception during the test;

    入选标准第 20 条

    Lactating women who are unwilling to stop breastfeeding;

    排除标准第 12 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06827782,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients with refractory/recurrent CNS lymphoma must meet all of the following criteria to be eligible:
  2. Voluntarily participate in the study and sign the informed consent;
  3. Age 18-75 years old, male or female;
  4. Diffuse large B-cell lymphoma (DLBCL) was confirmed by histology. CD19 expression was positive by lymphoma pathology or flow cytometry, and CD19 expression was ≥20% by IHC.
  5. Imaging showed no evidence of systemic lymphoma;
  6. Meets any of the following definitions for refractory/relapsed CNS lymphoma: no complete response has been achieved with prior 2-line regimen including methotrexate or cytarabine-based regimen; Disease progression during any treatment; The stable time of disease after effective treatment is less than 6 months; Disease progression or recurrence within 12 months after autologous hematopoietic stem cell transplantation.
  7. Imaging showed the presence of at least one measurable lesion, with a minimum diameter of ≥10mm;
  8. Expected survival ≥3 months;
  9. ECOG score 0-3 points;
  10. Adequate organ function reserve:
  11. alanine aminotransferase, ASpartate aminotransferase ≤ 2.5× UNL (upper limit of normal);
  12. Creatinine clearance (Cockcroft-Gault method) ≥60 mL/min;
  13. Serum total bilirubin and alkaline phosphatase ≤1.5× UNL;
  14. Glomerular filtration rate >50ml/min
  15. cardiac ejection fraction (EF) ≥45%;
  16. Basic oxygen saturation >92% in indoor natural air environment;
  17. Blood routine: absolute number of neutrophils >×109/L, platelet count 45×109/L, hemoglobin 80g/L;
  18. Previous autologous hematopoietic stem cell transplantation is allowed, and the interval between stem cell transfusion and CAR-NK transfusion is ≥3 months;
  19. Previous CAR-T cell therapy is allowed, and the time interval between CAR-T transfusion and CAR-NK transfusion is ≥3 months;
  20. Female subjects of childbearing age must test negative for pregnancy and agree to use effective contraception during the test;
  21. Approved anti-tumor therapies, such as systemic chemotherapy, whole body radiotherapy and immunotherapy, have been discontinued for at least 3 weeks before the study; Discontinuation of targeted drug regiments without chemotherapy for at least 2 weeks;

排除标准:Exclusion Criteria:

  1. Subjects who meet any of the following criteria will not be admitted to the study:
  2. Allergic to any of the components of cell products;
  3. History of other tumors;
  4. Acute grade II-IV (Glucksberg standard) GvHD or generalized chronic GvHD occurred after previous allogeneic hematopoietic stem cell transplantation; Or are receiving anti-GVHD treatment;
  5. Have received gene therapy within the past 3 months;
  6. Active infections requiring treatment (except simple urinary tract infections, bacterial pharyngitis), but prophylactic antibiotic, antiviral and antifungal infection treatment is permitted;
  7. Persons infected with hepatitis B (HBsAg positive, but HBV-DNA<103 is not excluded) or hepatitis C virus (including virus carriers), syphilis and other acquired and congenital immunodeficiency diseases, including but not limited to HIV-infected persons;
  8. Subjects with Grade III or IV cardiac dysfunction according to the New York Heart Association's cardiac function grading criteria;
  9. Patients who received antitumor therapy in the early stage but did not recover toxicity (CTCAE 5.0 toxicity did not recover to ≤ grade 1, except fatigue, anorexia, alopecia);
  10. Previous history of epilepsy, autoimmune encephalitis, cerebral infarction or cerebral hemorrhage within 6 months;
  11. Whole-body enhanced CT or PET/CT suggests evidence of systemic lymphoma;
  12. Lactating women who are unwilling to stop breastfeeding;
  13. Any other circumstances that the investigator believes may increase the risk to the subject or interfere with the test results;
  14. Patients requiring more than 10mg of dexamethasone per day for 3 days prior to enrollment;
  15. Patients who cannot tolerate ommaya capsule implantation;
  16. Those who cannot tolerate enhanced magnetic resonance imaging.

引自 ClinicalTrials.gov, NCT06827782, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06827782,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06827782